CN110534202A - A kind of system that the expression for Sox10 in triple negative breast cancer is analyzed - Google Patents
A kind of system that the expression for Sox10 in triple negative breast cancer is analyzed Download PDFInfo
- Publication number
- CN110534202A CN110534202A CN201910774575.1A CN201910774575A CN110534202A CN 110534202 A CN110534202 A CN 110534202A CN 201910774575 A CN201910774575 A CN 201910774575A CN 110534202 A CN110534202 A CN 110534202A
- Authority
- CN
- China
- Prior art keywords
- module
- data
- sox10
- breast cancer
- result
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/20—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Abstract
The present invention relates to data analysis system technical fields, the system that especially a kind of expression for Sox10 in triple negative breast cancer is analyzed, including network system management host and data transmission module, the network system management host is connected with multiple plan execution units and multiple planning management units by data transmission module, the plan execution unit is connected with power module by signal wire, module is submitted in plan, as a result module is submitted, parameter adapting module and data sampling module, electricity is provided by electric power source pair of module plan execution unit, module is submitted to submit the predetermined plan executed by plan, the experimental data in experimentation is acquired by data sampling module, module is submitted to submit experimental result by result, it is adjusted by planning of experiments of the parameter adapting module to execution, planning management unit is to meter The plan that execution unit proposes is drawn to be examined.The present invention can analyse expression of the Sox10 in triple negative breast cancer scientifically.
Description
Technical field
The present invention relates to data analysis system field more particularly to a kind of tables for Sox10 in triple negative breast cancer
Up to the system analyzed.
Background technique
Breast cancer is currently the primary malignant tumour of China's women disease incidence, and disease incidence is also rising year by year, seriously
Threaten the physical and mental health of female patient.In breast cancer molecular parting triple negative breast cancer lack expression estrogen receptor (ER),
Progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), much research shows that triple negative breast cancer patient accounts for totality
The 10%-15% of patient with breast cancer, it is in the majority with Hispanic and non-descendants' American Women.But China's women triple negative breast cancer is suffered from
Person accounts for the 12%-20% of overall patient with breast cancer, is much higher than other western countries.Triple negative breast cancer is often broken up poor, is invaded
Attacking property is high, high recurrence rate, is easy transfer, prognosis is poor compared with other types breast cancer, is the emphasis and hot spot of current breast cancer research.
In the pathological diagnosis of breast cancer, the specific immunity group marker diagnosed for primary or metastatic breast cancer is not
It is more.Since triple negative breast cancer is easy transfer, and ER, PR are not expressed, for its transfer stove, sometimes more difficult and other position sources
Adenocarcinoma metastatic identifies, and usually perplexs to the pathological diagnosis work belt of inventor, therefore need to filter out some in three negative creams
The higher marker of sensibility and specificity in gland cancer, to facilitate inventor timely and accurately to make primary or three yin of metastatic
Property breast cancer diagnosis and instruct inventor to breast cancer carry out parting.
Immunohistochemistry (IHC) has become the indispensable tool of auxiliary pathological diagnosis.Make in conjunction with tectology
Tissue specificity IHC marker is particularly helpful to identify the tumour in unknown source.The work of inventor's pathological diagnosis before is worked as
In, the immunohistochemical markers object that Diagnosis of Breast cancer or metastatic breast cancer usually use has cystic disease liquid protein -15
(gross cystic disease fluid protein, GCDFP-15) and mammaglobin (mammaglobin, MGB).
GCDFP-15 is the biggish constitutive protein of one of breast cyst fluid, can be in acinus and apocrine sweat gland body of gland including mammary gland salivary gland
And it is expressed in any cell with apocrine sweat gland feature of Paget disease at the positions such as skin and vulva.It is only few in addition to breast cancer
Several tumour such as prostate cancers of number, the cancer in appendages of skin source can express the albumen【7】.Therefore it for breast cancer have compared with
High specificity, and be commonly used as assessing the immunohistochemistry mark in the potential mammary gland source of unknown original site metastatic carcinoma
Note.MGB is the secreting type differentially expressed protein that the molecular weight 10kD come is cloned from breast cancer epithelial cell, is ground through many
Study carefully the more specific marker that confirmation is also Diagnosis of Breast cancer.Both immune markers specificity in breast cancer is equal
Preferably, but sensibility is all poor, especially in the higher breast cancer of rank such as triple negative breast cancer.
Research is thought before, and Sox10 expression is dashed forward less in the schwann cells of peripheral nerve, epidermal melanophore, cerebral cortex
Spongiocyte, mast cell, the musculoepithelia cell of submucosa bronchial gland, the acinus of mammary gland and salivary gland, musculoepithelia cell and
A variety of epithelium class cells of cochlea lateral wall, remaining tissue have no expression, and Sox10 Immunohistochemical Labelling is mainly seen in black
Plain tumor, peripheral nerve sheath tumour and myoepithelioma of salivary gland.Therefore Sox10 immunohistochemical staining can be with these tumours of auxiliary diagnosis.
Studies have found that, Sox10 can be in primary breast cancer, mainly substrate sample breast cancer, non-classified three negative breast in recent years
It is expressed in cancer.However in the prior art there is no the system analyzed and researched for this expression, it is objective also to make
The evaluation of science, and obtain convictive conclusion.
Summary of the invention
The purpose of the present invention is to solve exist in the prior art be not easy to scientific analysis the shortcomings that, and propose one kind
The system analyzed for expression of the Sox10 in triple negative breast cancer.
To achieve the above objectives, the technical solution adopted by the present invention are as follows: it is a kind of for Sox10 in triple negative breast cancer
The system analyzed, including network system management host and data transmission module are expressed, the network system management host is passed by data
Defeated module is connected with multiple plan execution units and multiple planning management units, and network system management host is complete to the experiment in system
Process is monitored and provides data storage and Analysis Service, plans member in execution unit docking system, planning management unit
The manager of experimentation is docked, the plan execution unit is connected with power module by signal wire, module is submitted in plan, knot
Fruit submits module, parameter adapting module and data sampling module, provides electricity by electric power source pair of module plan execution unit, passes through
Plan submits module to submit the predetermined plan executed, is adopted by data sampling module to the experimental data in experimentation
Collection is submitted module to submit experimental result, is adjusted by planning of experiments of the parameter adapting module to execution by result
Whole, the plan that planning management unit proposes plan execution unit is examined.
Preferably, the plan submits module by signal to be connected with method setting module, by method setting module to predetermined
The planning process of execution carries out the setting of method.
Preferably, the result submits module to be connected with by signal wire and module is locally stored, and submits module by result
Experimental result is recorded, and is stored in and module is locally stored, the data of storage can be total to by data transmission module
It enjoys that system is each to be locally stored in module, realizes coming into the open for data so as to facilitate, and can be improved data preservation
Safety.
Preferably, the planning management unit is connected with experimental group module, the experimental group module by signal wire
Experimental subjects is grouped, according to the principle being grouped at random, to guarantee the accuracy of experimental result.
Preferably, the planning management unit is connected with Program Assessment module and risk evaluation module, institute by signal wire
It states Program Assessment module to analyze the plan of submission, analyzes its feasibility, the risk evaluation module is to planning of experiments
No there are risks to be assessed, so that Added Management person judges whether the progress of approval experiment.
Preferably, the planning management unit is connected with key login module by signal wire, and manager is stepped on by key
Module is recorded by authentication, so that it is determined that the identity of manager.
Preferably, the network system management host is connected with data memory module and outcome evaluation module, institute by signal wire
It states data memory module and storage backup is carried out to experimental data, outcome evaluation module assesses the test result of upload.
Preferably, the outcome evaluation module includes the data classification mould being connect by signal wire with network system management host
Block, data categorization module classify to the experimental result data stored in data memory module, and the data categorization module is logical
It crosses data line and is connected with data statistics module, data statistics module counts sorted data, the data statistics mould
Block is connected with sensitivity analysis module and specific analysis module, sensitivity analysis module and characteristic shape module pair by signal wire
Statistical result carries out the analysis of sensibility and specificity, and the sensitivity analysis module and specific analysis module pass through signal wire
It is connected with diagrammatic representation module jointly, the diagrammatic representation module, which passes through, intuitively to be shown to analysis result by chart
Signal wire is connected with result publicity module, and as a result publicity module is shown the chart of generation, passes through mail or website
Mode is shown.
Preferably, the network system management host is connected with authentication module and priority assignation module by signal wire, leads to
It crosses authentication module to verify manager's identity of login system managing main frame, priority assignation module executes list to plan
The system permission of member user corresponding with planning management unit is configured.
Preferably, execute process the following steps are included:
S1, management system is established；
S2, system operator set permission to member in system；
S3, user's login plan execution unit as experiment executor, and planning of experiments is submitted, and formulate experiment
Method modifies to experimental method by parameter adapting module；
S4, user's login planning management unit as experiment management person, and the planning of experiments of submission is examined；
S5, experiment execution, experimental data is acquired by data sampling module, submits module to adopting by result
The data of collection are uploaded, and are stored by the way that module is locally stored to data, and experimentation includes: to collect cancer sample, are owned
Sample is routinely dehydrated paraffin embedding after 10% formalin is fixed, and serial section is cut into 4 μm of slabs, a progress HE
Dyeing, so that experienced pathologist is for confirming pathological diagnosis, remaining is used for immunohistochemical staining, ER, PR, Her-2,
Ki67, GATA-3, FOXA1, Sox10, GCDFP15, MGB carry out immune group with the full-automatic immunohistochemistry instrument of Roche Ventana XT
Change dyeing；ER, PR, ki67, GATA-3, FOXA1, the Sox10 positive are positioned at nucleus, and the HER-2 positive is positioned at cell membrane,
GCDFP15 and MGB is positioned at endochylema, and stained positive signal is in brown color, and immunohistochemical staining result is by two pathologists point
It is not assessed, 400 times of high power microscopic observation at least five visuals field take its average value to determine, ER, PR, GATA-3, FOXA1,
Sox10, GCDFP15 and MGB are by positive cell proportion: positive cell number >=1% is judged to the positive.Her-2 according to
2018ASCO/CAP guide carries out interpretation；
S6, the data being locally stored are realized in system by data transmission module and are shared, and upload to system pipes
It manages host and realizes backup；
The assessment of S7, experimental result.
Compared with prior art, the invention has the following advantages:
1, the present invention is provided with network system management host and multiple plan execution units and planning management unit, passes through plan
Execution unit and planning management unit, which can facilitate, to carry out and is supervised while realizing multiple plannings of experiments, the operation effect of system
Rate is high, and under the management of network system management host, can science it is for statistical analysis to experimental result and obtained science according to
According to conclusion so that analysis result more there is convincingness.
2, the marker that Sox10 is diagnosed possible as mammary gland musculoepithelia cell and triple negative breast cancer is concluded that, especially
It is the preferable one group of diagnosis and antidiastole that Sox10 joint GATA-3 may be primary and metastatic triple negative breast cancer
Marker；Sox10 is likely to become a kind of new biomarker of prediction primary triple negative breast cancer prognosis and transfer ability
With the potential target gene of triple negative breast cancer treatment.
Detailed description of the invention
Fig. 1 is system block diagram of the invention；
Fig. 2 is the system block diagram of outcome evaluation module of the invention.
Specific embodiment
It is described below for disclosing the present invention so that those skilled in the art can be realized the present invention.It is excellent in being described below
Embodiment is selected to be only used as illustrating, it may occur to persons skilled in the art that other obvious modifications.
The system that a kind of expression for Sox10 in triple negative breast cancer as shown in Figs. 1-2 is analyzed, including be
Unite managing main frame and data transmission module, network system management host by data transmission module be connected with multiple plan execution units with
Multiple planning management units, network system management host are monitored and are provided to the overall process of the experiment in system data storage and divide
Member in execution unit docking system is planned in analysis service, and planning management unit docks the manager of experimentation, and plan executes list
Member is connected with power module by signal wire, module is submitted in plan, result submits module, parameter adapting module and data sampling mould
Block provides electricity by electric power source pair of module plan execution unit, submits module to submit the predetermined plan executed by plan, passes through
Data sampling module is acquired the experimental data in experimentation, submits module to propose experimental result by result
It hands over, is adjusted by planning of experiments of the parameter adapting module to execution, planning management unit proposes plan execution unit
Plan is examined.Plan submits module by signal to be connected with method setting module, by method setting module to predetermined execution
The setting of planning process progress method.
As a result submit module to be connected with by signal wire module is locally stored, by result submission module to experimental result into
Row record, and be stored in and module is locally stored, it can be each to system by the data sharing of storage by data transmission module
It is locally stored in module, realizes coming into the open for data so as to facilitate, and can be improved the safety of data preservation.Plan pipe
It manages unit and experimental group module is connected with by signal wire, experimental group module is grouped experimental subjects, according to random point
The principle of group, to guarantee the accuracy of experimental result.Planning management unit is connected with Program Assessment module and wind by signal wire
Dangerous evaluation module, Program Assessment module analyze the plan of submission, analyze its feasibility, and risk evaluation module counts experiment
It draws and is assessed with the presence or absence of risk, so that Added Management person judges whether the progress of approval experiment.
Planning management unit is connected with key login module by signal wire, and manager passes through body by key login module
Part verifying, so that it is determined that the identity of manager.Network system management host is connected with data memory module by signal wire and result is commented
Estimate module, data memory module carries out storage backup to experimental data, and outcome evaluation module comments the test result of upload
Estimate.
Outcome evaluation module includes the data categorization module being connect by signal wire with network system management host, data classification mould
Block classifies to the experimental result data stored in data memory module, and data categorization module is connected with data by data line
Statistical module, data statistics module count sorted data, and data statistics module is connected with sensitivity by signal wire
Property analysis module and specific analysis module, sensitivity analysis module and characteristic shape module sensibility and spy are carried out to statistical result
Anisotropic analysis, sensitivity analysis module and specific analysis module are connected with diagrammatic representation module by signal wire jointly, lead to
It crosses chart and diagrammatic representation module, which is connected with result publicity module by signal wire, as a result is intuitively shown to analysis result
Publicity module is shown the chart of generation, is shown by way of mail or website.
Network system management host is connected with authentication module and priority assignation module by signal wire, passes through authentication mould
Block verifies manager's identity of login system managing main frame, and priority assignation module is to plan execution unit and planning management
The system permission of the corresponding user of unit is configured.
Execute process the following steps are included:
S1, management system is established；
S2, system operator set permission to member in system；
S3, user's login plan execution unit as experiment executor, and planning of experiments is submitted, and formulate experiment
Method modifies to experimental method by parameter adapting module；
S4, user's login planning management unit as experiment management person, and the planning of experiments of submission is examined；
S5, experiment execution, experimental data is acquired by data sampling module, submits module to adopting by result
The data of collection are uploaded, and are stored by the way that module is locally stored to data；
S6, the data being locally stored are realized in system by data transmission module and are shared, and upload to system pipes
It manages host and realizes backup；
The assessment of S7, experimental result.
Experimental method is illustrated below with reference to example:
1. material and method
1.1 material
Collect the primary wellability of operation excision pathology department, affiliated hospital, Southern Yangtze University in December, -2013 in January, 2010
Breast cancer sample 376 (only including duct carcinoma and lobular carcinoma), the excision of in January, 2016 underwent operative in December, -2018 or biopsy
Metastatic breast cancer sample (only including duct carcinoma and lobular carcinoma) 77 and 50, benign breast tissue.All primary wellabilities
Preoperative any radiotherapy and the chemotherapy of not going of patient with breast cancer.All samples through HE dye and immunohistochemical staining after by our hospital two
High seniority pathologist is made a definite diagnosis.All cases have complete postoperative pathological data.It is international early according to version St.Gallen in 2017
Primary breast cancer primary care Consensus of experts carries out molecule parting to breast cancer.Due to Molecular Detection sample is required it is high, detection at
This height, therefore be difficult clinically to be widely applied, thus usually with the method for immunohistochemistry replace Molecular Detection to breast cancer into
Row molecule parting.ER, PR are detected with Immunohistochemical Method, ki-67 expression is detected with Immunohistochemical Method or hybridization in situ technique
Whether Her-2 gene is overexpressed or expands.Because being difficult to define a Ki67 index section, examined at present with Immunohistochemical Method
Surveying Ki67 index, there is also certain controversials.Section of the inventor's use for laboratory 15% as Ki67 index.Inventor accordingly
The primary infiltrative breast carcinoma and metastatic breast cancer that are collected into are divided into three molecular isoforms: Luminal (A and B) (n=
240), Her-2 overexpression type (n=65) and three female (n=71)；Luminal (A and B) (n=44), Her-2 overexpression type (n
=11), three female (n=22).
To 71 primary triple negative breast cancer patient follow-ups since postoperative, by October, 2018 follow-up period expire 5
Year, disease-free survival 25, recurrence or transfer 46 (wherein simple hepatic metastases 12, simple Lung metastases 13, simple Bone tumours 6
Example, simple brain metastes 7, soft tissue shift 2, multiple transfer 6), wherein because transfer leads to dead 23.Primary breast
The clinical stages standard of cancer is according to International Union Against Cancer (Union for International Cancer Control, UICC)
The clinical stages formulated with american cancer joint committee (American Joint Commission for Cancer, AJCC)
Standard carries out.Histological grade is according to Nottingham united organization histological grading (NottinghamCombined Histology
Grade) standard carries out.
1.2 method
Institute is routinely dehydrated paraffin embedding after 10% formalin is fixed in a organized way, and serial section is cut into cutting for 4 μ m-thicks
Piece.One progress HE dyeing, so that experienced pathologist is for confirming pathological diagnosis, remaining is used for immunohistochemical staining.
ER, PR, Her-2, ki67, GATA-3, FOXA1, Sox10, GCDFP15, the MGB full-automatic immunohistochemistry of Roche Ventana XT
Instrument carries out immunohistochemical staining.ER, PR, ki67, GATA-3, FOXA1, Sox10, GCDFP15, MGB monoclonal antibody are purchased from
Shanghai Gene Tech. Company Limited.HER-2 monoclonal antibody is purchased from Roche Holding Ag.Fluorescence in situ hybridization (FISH) is for detecting
HER-2 gene magnification, FISH detection kit are purchased from Abbott.
1.3 result interpretations
ER, PR, ki67, GATA-3, FOXA1, the Sox10 positive are positioned at nucleus, and the HER-2 positive is positioned at cell membrane,
GCDFP15 and MGB is positioned at endochylema, and stained positive signal is in brown color.Immunohistochemical staining result is by two pathologists point
It is not assessed.400 times of high power microscopic observation at least five visuals field, take its average value to determine, ER, PR, GATA-3, FOXA1,
Sox10, GCDFP15 and MGB are by positive cell proportion: positive cell number >=1% is judged to the positive.Her-2 according to
2018ASCO/CAP guide carries out interpretation.
1.4 statistical analysis
Statistical procedures are carried out using 23.0 statistics software of SPSS, are inspection level with P < 0.05.Using X2 examine and
Fisher exact propability analyzes each group difference.
2, method
Institute is routinely dehydrated paraffin embedding after 10% formalin is fixed in a organized way, and serial section is cut into cutting for 4 μ m-thicks
Piece.One progress HE dyeing, so that experienced pathologist is for confirming pathological diagnosis, remaining is used for immunohistochemical staining.
ER, PR, Her-2, ki67, GATA-3, FOXA1, Sox10, GCDFP15, the MGB full-automatic immunohistochemistry of Roche Ventana XT
Instrument carries out immunohistochemical staining.ER, PR, ki67, GATA-3, FOXA1, Sox10, GCDFP15, MGB monoclonal antibody are purchased from
Shanghai Gene Tech. Company Limited.HER-2 monoclonal antibody is purchased from Roche Holding Ag.Fluorescence in situ hybridization (FISH) is for detecting
HER-2 gene magnification, FISH detection kit are purchased from Abbott.
3, result interpretation
ER, PR, ki67, GATA-3, FOXA1, the Sox10 positive are positioned at nucleus, and the HER-2 positive is positioned at cell membrane,
GCDFP15 and MGB is positioned at endochylema, and stained positive signal is in brown color.Immunohistochemical staining result is by two pathologists point
It is not assessed.400 times of high power microscopic observation at least five visuals field, take its average value to determine, ER, PR, GATA-3, FOXA1,
Sox10, GCDFP15 and MGB are by positive cell proportion: positive cell number >=1% is judged to the positive.Her-2 according to
2018ASCO/CAP guide carries out interpretation.
4, statistical analysis
Statistical procedures are carried out using 23.0 statistics software of SPSS, are inspection level with P < 0.05.Using X2 examine and
Fisher exact propability analyzes each group difference.
2 results
Expression of 2.1 Sox10 in normal galactophore tissue；
50 normal galactophore tissue's myoepithelium Sox10 positive rates are 100% (50/50).In mammary gland lumen of gland cell and interstitial
Fibroblast is showed no Sox10 expression (Fig. 1).
The ratio of 2.2 Sox10 expression in different molecular hypotype primary infiltrative breast carcinoma and metastatic breast cancer
Compared with；
Sox10 positive rate in Luminal type, Her-2 overexpression type and three negative primary breast cancers is respectively 0%,
3.1% and 67.6% (Fig. 2).Positive rate in the metastatic breast cancer of three kinds of molecular isoforms is respectively 0%, 9.10%,
68.18%.Either in three female breast cancer of primary or metastatic, the positive rate of Sox10 is bright compared with other molecular isoforms
Aobvious height, difference have conspicuousness (P < 0.001, P < 0.001).
2.3 Sox10 and GATA-3, FOXA1, GCDFP15, MGB are in three female breast cancer of primary and three female of metastatic
Sensibility, the specificity of breast carcinoma compare:
Sox10, the GATA-3 sensibility in three female breast cancer of primary are respectively 67.60%, 87.32%, specificity
Respectively 31.58%, 40.79%；Sensibility in three female breast cancer of metastatic is respectively 68.18%, 86.36%, special
The opposite sex is respectively 32.61%, 41.3%.Compared with other markers, either in three female mammary gland of primary or metastatic
The sensibility and specificity of cancer, Sox10 is only below GATA-3, and obviously higher than FOXA1, GCDFP15, MGB, difference all has aobvious
Work property (P < 0.001, P=0.0004, P=0.0064, P=0.0229).
Relationship between the expression and primary triple negative breast cancer clinical pathologic characteristic of 2.4 Sox10:
In 71 primary triple negative breast cancers, the expression of Sox10 is related to pathologic grading of cancer, is classified in high tumour
The height of the lower intermediate tumour of the positive rate of Sox10, difference have conspicuousness (P=0.0145)；It is also related with clinical stages, by stages
The positive rate of the tumour Sox10 in evening is high (P=0.0105) compared with early metaphase tumer positive rate；It is related with lymphatic metastasis, lymph node
The positive rate of the tumour Sox10 of transfer number four or more is compared with the tumour that no lymphatic metastasis and lymphatic metastasis number are 1-3
Positive rate it is high (P=0.0249).With some other clinical pathologic characteristic of primary triple negative breast cancer such as age of onset, tumour
The non-correlations such as diameter and histological type.
Correlation between the expression of 2.5 Sox10 and primary triple negative breast cancer prognosis:
Kaplan-Merier the survival analysis expression of Sox10 and primary triple negative breast cancer patient as the result is shown
DFS phase it is related.More negative group of the DFS phase of Sox10 positive group is obvious in 71 primary triple negative breast cancers
Low, difference has conspicuousness (P=0.007).
The marker that conclusion Sox10 is diagnosed possible as mammary gland musculoepithelia cell and triple negative breast cancer, especially
Sox10 joint GATA-3 may be preferable one group of diagnosis and the antidiastole mark of primary and metastatic triple negative breast cancer
Object；Sox10 is likely to become a kind of new biomarker and three of prediction primary triple negative breast cancer prognosis and transfer ability
The potential target gene of negative breast cancer treatment.
The basic principles, main features and advantages of the present invention have been shown and described above.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and what is described in the above embodiment and the description is only the present invention
Principle, various changes and improvements may be made to the invention without departing from the spirit and scope of the present invention, these variation and
Improvement is both fallen in the range of claimed invention.The present invention claims protection scope by appended claims and its
Equivalent defines.
Claims (10)
1. a kind of system that the expression for Sox10 in triple negative breast cancer is analyzed, including network system management host sum number
According to transmission module, which is characterized in that the network system management host is connected with multiple plan execution units by data transmission module
With multiple planning management units, network system management host the overall process of the experiment in system is monitored and provide data storage and
Analysis Service, plans member in execution unit docking system, and planning management unit docks the manager of experimentation, the plan
Execution unit is connected with power module by signal wire, module is submitted in plan, result submits module, parameter adapting module and data
Sampling module provides electricity by electric power source pair of module plan execution unit, submits module to submit the predetermined meter executed by plan
It draws, the experimental data in experimentation is acquired by data sampling module, submit module to experimental result by result
It is submitted, is adjusted by planning of experiments of the parameter adapting module to execution, planning management unit is to plan execution unit
The plan of proposition is examined.
2. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the plan submits module by signal to be connected with method setting module, by method setting module to predetermined execution
The setting of planning process progress method.
3. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the result submits module to be connected with by signal wire and module is locally stored, and submits module to experiment by result
As a result it is recorded, and is stored in and module is locally stored, it can be by the data sharing of storage to being by data transmission module
Unite it is each be locally stored in module, realize that data come into the open so as to facilitate, and can be improved the safety of data preservation.
4. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the planning management unit is connected with experimental group module by signal wire, and the experimental group module is to experiment
Object is grouped, according to the principle being grouped at random, to guarantee the accuracy of experimental result.
5. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the planning management unit is connected with Program Assessment module and risk evaluation module, the plan by signal wire
Evaluation module analyzes the plan of submission, analyzes its feasibility, and the risk evaluation module whether there is planning of experiments
Risk is assessed, so that Added Management person judges whether the progress of approval experiment.
6. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the planning management unit is connected with key login module by signal wire, and manager passes through key login module
By authentication, so that it is determined that the identity of manager.
7. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the network system management host is connected with data memory module and outcome evaluation module, the data by signal wire
Memory module carries out storage backup to experimental data, and outcome evaluation module assesses the test result of upload.
8. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the outcome evaluation module includes the data categorization module being connect by signal wire with network system management host, data
Categorization module classifies to the experimental result data stored in data memory module, and the data categorization module passes through data line
It is connected with data statistics module, data statistics module counts sorted data, and the data statistics module passes through letter
Number line is connected with sensitivity analysis module and specific analysis module, and sensitivity analysis module and characteristic shape module are to statistical result
The analysis of sensibility and specificity is carried out, the sensitivity analysis module and specific analysis module are connected jointly by signal wire
There is diagrammatic representation module, the diagrammatic representation module is connected by signal wire intuitively to be shown to analysis result by chart
It is connected to result publicity module, as a result publicity module is shown the chart of generation, carries out by way of mail or website
It shows.
9. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, the network system management host is connected with authentication module and priority assignation module by signal wire, passes through identity
Authentication module verifies manager's identity of login system managing main frame, and priority assignation module is to plan execution unit and meter
The system permission for drawing the corresponding user of administrative unit is configured.
10. the system that a kind of expression for Sox10 in triple negative breast cancer according to claim 1 is analyzed,
It is characterized in that, execute process the following steps are included:
S1, management system is established；
S2, system operator set permission to member in system；
S3, user's login plan execution unit as experiment executor, and planning of experiments is submitted, and formulate experimental method
Or it is modified by parameter adapting module to experimental method；
S4, user's login planning management unit as experiment management person, and the planning of experiments of submission is examined；
S5, experiment execution, experimental data is acquired by data sampling module, by result submit module to acquisition
Data are uploaded, and are stored by the way that module is locally stored to data, and experimentation includes: to collect cancer sample, all samples
It is routinely dehydrated paraffin embedding after 10% formalin is fixed, serial section is cut into 4 μm of slabs, a progress HE dye
Color, so that experienced pathologist is for confirming pathological diagnosis, remaining is used for immunohistochemical staining, ER, PR, Her-2,
Ki67, GATA-3, FOXA1, Sox10, GCDFP15, MGB carry out immune group with the full-automatic immunohistochemistry instrument of Roche Ventana XT
Change dyeing；ER, PR, ki67, GATA-3, FOXA1, the Sox10 positive are positioned at nucleus, and the HER-2 positive is positioned at cell membrane,
GCDFP15 and MGB is positioned at endochylema, and stained positive signal is in brown color, and immunohistochemical staining result is by two pathologists point
It is not assessed, 400 times of high power microscopic observation at least five visuals field take its average value to determine, ER, PR, GATA-3, FOXA1,
Sox10, GCDFP15 and MGB are by positive cell proportion: positive cell number >=1% is judged to the positive, Her-2 according to
2018ASCO/CAP guide carries out interpretation；
S6, the data being locally stored are realized in system by data transmission module and are shared, and upload to system administration master
Machine realizes backup；
The assessment of S7, experimental result.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910774575.1A CN110534202A (en) | 2019-08-21 | 2019-08-21 | A kind of system that the expression for Sox10 in triple negative breast cancer is analyzed |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910774575.1A CN110534202A (en) | 2019-08-21 | 2019-08-21 | A kind of system that the expression for Sox10 in triple negative breast cancer is analyzed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110534202A true CN110534202A (en) | 2019-12-03 |
Family
ID=68662448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910774575.1A Pending CN110534202A (en) | 2019-08-21 | 2019-08-21 | A kind of system that the expression for Sox10 in triple negative breast cancer is analyzed |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110534202A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111402986A (en) * | 2020-03-14 | 2020-07-10 | 无锡市第九人民医院 | Research system for ultrasonic quantitative mechanical evaluation of flexor digitorum profundus tendon based on different rehabilitation schemes |
| CN112391331A (en) * | 2020-11-12 | 2021-02-23 | 江南大学 | Recombinant escherichia coli for overexpression of GatA gene and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101182571A (en) * | 2007-12-06 | 2008-05-21 | 华南农业大学 | Animals toxoplasmosis PCR detection reagent kit |
| CN105722994A (en) * | 2013-06-17 | 2016-06-29 | 维里纳塔健康公司 | Method for determining copy number variations in sex chromosomes |
| CN107750277A (en) * | 2014-12-12 | 2018-03-02 | 维里纳塔健康股份有限公司 | Determine that copy number changes using Cell-free DNA clip size |
| CN108885648A (en) * | 2016-02-09 | 2018-11-23 | 托马生物科学公司 | System and method for analyzing nucleic acid |
| CN109355435A (en) * | 2018-11-23 | 2019-02-19 | 深圳市刚竹医疗科技有限公司 | The nucleic acid compositions and H7N9 virus real-time fluorescence immue quantitative detection reagent box of H7N9 viral diagnosis and its application |
| CN109880905A (en) * | 2019-03-22 | 2019-06-14 | 复旦大学附属肿瘤医院 | One group of gene and its application for triple negative breast cancer immunohistochemistry parting |
-
2019
- 2019-08-21 CN CN201910774575.1A patent/CN110534202A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101182571A (en) * | 2007-12-06 | 2008-05-21 | 华南农业大学 | Animals toxoplasmosis PCR detection reagent kit |
| CN105722994A (en) * | 2013-06-17 | 2016-06-29 | 维里纳塔健康公司 | Method for determining copy number variations in sex chromosomes |
| CN107750277A (en) * | 2014-12-12 | 2018-03-02 | 维里纳塔健康股份有限公司 | Determine that copy number changes using Cell-free DNA clip size |
| CN108885648A (en) * | 2016-02-09 | 2018-11-23 | 托马生物科学公司 | System and method for analyzing nucleic acid |
| CN109355435A (en) * | 2018-11-23 | 2019-02-19 | 深圳市刚竹医疗科技有限公司 | The nucleic acid compositions and H7N9 virus real-time fluorescence immue quantitative detection reagent box of H7N9 viral diagnosis and its application |
| CN109880905A (en) * | 2019-03-22 | 2019-06-14 | 复旦大学附属肿瘤医院 | One group of gene and its application for triple negative breast cancer immunohistochemistry parting |
Non-Patent Citations (3)
| Title |
|---|
| 北京天健通泰科技有限公司: "实验室综合管理系统功能简述！", 《网页在线公开：WENKU.BAIDU.COM/VIEW/43D6795FB80D6C85EC3A87C24028915F814D8467.HTML》 * |
| 文娟娟: "SOX10在人体常见上皮性肿瘤中的表达及其临床病理学意义", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 程凯等: "乳腺癌组织中SOX10 的表达及其临床意义", 《临床与实验病理学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111402986A (en) * | 2020-03-14 | 2020-07-10 | 无锡市第九人民医院 | Research system for ultrasonic quantitative mechanical evaluation of flexor digitorum profundus tendon based on different rehabilitation schemes |
| CN112391331A (en) * | 2020-11-12 | 2021-02-23 | 江南大学 | Recombinant escherichia coli for overexpression of GatA gene and application thereof |
| CN112391331B (en) * | 2020-11-12 | 2022-09-27 | 江南大学 | Recombinant escherichia coli for overexpression of GatA gene and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baak et al. | Ein and who94 | |
| Diamond et al. | A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness | |
| Scolyer et al. | Pathologic examination of sentinel lymph nodes from melanoma patients | |
| US20110111435A1 (en) | Detecting Cell Surface Markers | |
| US8891850B2 (en) | System and methods for digital evaluation of cellblock preparations | |
| WO2022012280A1 (en) | Peripheral blood tcr marker for lung cancer, detection kit therefor and application thereof | |
| Mairinger et al. | Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma | |
| Pradhan et al. | Grading, staging and Nottingham prognostic index scoring of breast carcinoma | |
| Mudhar et al. | Fluorescence in situ hybridisation (FISH) in histologically challenging conjunctival melanocytic lesions | |
| CN110534202A (en) | A kind of system that the expression for Sox10 in triple negative breast cancer is analyzed | |
| Barroca et al. | A basic approach to lymph node and flow cytometry fine-needle cytology | |
| Taniuchi et al. | A novel clinically-oriented classification of fine-needle aspiration cytology for salivary gland tumors: a 20-year retrospective analysis of 1175 patients | |
| CN111665357A (en) | Extranodal nasal NK/T cell lymphoma prognosis marker, application thereof, prognosis prediction model and construction method thereof | |
| Fitzgibbons et al. | Protocol for the examination of resection specimens from patients with invasive carcinoma of the breast | |
| Gong | Breast cancer: Pathology, cytology, and core needle biopsy methods for diagnosis | |
| Yildiz et al. | Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies | |
| Xie et al. | Artificial intelligence scale-invariant feature transform algorithm-based system to improve the calculation accuracy of Ki-67 index in invasive breast cancer: a multicenter retrospective study | |
| McManus et al. | Fine needle aspiration cytology of the breast | |
| Viale | Histopathology of primary breast cancer 2003 | |
| Nassif et al. | Milan system for reporting salivary gland cytopathology: Adoption and outcomes in a community setting | |
| CN104007217A (en) | Serum protein fingerprint spectrum diagnosis model for screening thyroid cancer and establishment method for serum protein fingerprint spectrum diagnosis model | |
| Agrawal et al. | Nalini Bai Thakkar Award | |
| Böcking et al. | Prediction of non-progression in prostate cancer patients under Active Surveillance by DNA karyometry | |
| Kothari et al. | Spectrum of lesions encountered and accuracy of core needle biopsy of breast | |
| Chhieng et al. | Intraoperative Evaluation of Sentinel Lymph Nodes in Breast Cancer Patients Using Touch Preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191203 |